# Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

> **NCT01365910** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** linifanib

## Key facts

- **NCT ID:** NCT01365910
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-05
- **Final completion:** 2013-06
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Interim analysis determined the study did not meet criteria to proceed
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01365910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01365910, "Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01365910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*